Related Experiment Video

Updated: Oct 23, 2025

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.0K

A Review of the Design and Implementation of a Hybrid Cardiac Rehabilitation Program: AN EXPANDING OPPORTUNITY FOR

Steven J Keteyian1, Philip A Ades, Alexis L Beatty

  • 1Division of Cardiovascular Medicine, Henry Ford Health System, Detroit, Michigan (Dr Keteyian); University of Vermont Larner College of Medicine, Burlington (Dr Ades); Department of Epidemiology and Biostatistics and Division of Cardiology, University of California San Francisco, San Francisco (Dr Beatty), Northwest Community Healthcare, Arlington Heights, Illinois (Ms Gavic-Ott); Abt Associates, Rockville, Maryland (Dr Hines); Advocate for Action, LLC, Gainesville, GA (Ms Lui); Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland (Dr Schopfer); Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota (Dr Thomas); and Center for Heart Disease Prevention, Emory University School of Medicine, Atlanta, Georgia (Dr Sperling).

Journal of Cardiopulmonary Rehabilitation and Prevention
|August 26, 2021
PubMed

Insights

Hybrid cardiac rehabilitation (HYCR) combines facility-based and remote programs to increase patient participation. This approach is crucial for overcoming barriers and achieving higher cardiac rehabilitation (CR) rates.

Area of Science:

  • Cardiology
  • Rehabilitation Medicine
  • Health Services Research

Background:

  • Facility-based cardiac rehabilitation (FBCR) is effective but has limited reach.
  • The Million Hearts Initiative aims to increase CR participation to 70% by 2022.
  • Barriers like geography and work limit FBCR access for many patients.

Purpose of the Study:

  • To review the design and implementation of hybrid cardiac rehabilitation (HYCR) programs.
  • To identify strategies for increasing CR participation beyond FBCR.
  • To provide practical guidance for developing and delivering HYCR.

Main Methods:

  • Literature review focused on HYCR design and implementation.
  • Analysis of studies on exercise programming, patient monitoring, and outcomes.
  • Examination of strategies for billing, reimbursement, and engagement.

Main Results:

  • HYCR programs integrate facility-based and virtual/remote CR components.
  • Key considerations include exercise prescription, safety, patient monitoring, and education.
  • Billing, insurance, and engagement strategies are essential for successful implementation.

Conclusions:

  • HYCR is necessary to supplement FBCR and meet participation goals.
  • Further research is needed to optimize HYCR programming.
  • HYCR offers a flexible solution for patients facing access barriers to traditional CR.
Abstract

More Related Videos

A Real-World High-Intensity Interval Training Protocol for Cardiorespiratory Fitness Improvement08:27

A Real-World High-Intensity Interval Training Protocol for Cardiorespiratory Fitness Improvement

Published on: February 22, 2022

3.3K
Walk with Me Hybrid Virtual/In-Person Walking for Older Adults with Neurodegenerative Disease07:21

Walk with Me Hybrid Virtual/In-Person Walking for Older Adults with Neurodegenerative Disease

Published on: June 16, 2023

1.1K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
69
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
97
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
52
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
84
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
72
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
62